International Journal of Endocrinology / 2013 / Article / Tab 5

Clinical Study

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 5

Changes in fat distribution on CT scanning.

ParametersGroup0 month12 monthsP-valueDifferenceP-value

Visceral fat area (cm2)T 0.695
L 0.345 0.353
Subcutaneous fat area (cm2)T 0.875
L 0.834 0.933
Visceral to subcutaneous fat ratioT 0.754
L 0.176 0.398
Liver to spleen ratioT 0.049
L >0.999 0.272

Data are presented as mean SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney test.
CT: computer tomography.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.